July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–a...

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherap...

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything ab...

The ASCO Post

July 24, 2026

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), i...

The ASCO Post

July 24, 2026

EMERALD-3 Shows Benefit With STRIDE Plus TACE in Hepatocellular Carcinoma

Results of the phase III EMERALD-3 trial showed that combining transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE regimen, (single tremelimumab[an anti-cytotoxic T lymphocyte–a...

The ASCO Post

July 24, 2026

Paving New ROADS in the Treatment of Brain Metastases With Implanted Tile-Based Radiation Therapy

Tile-based radiation therapy (TBRT) implanted at the time of resection outperformed standard postoperative stereotactic radiation therapy (SRT) in the phase III Radiation One and Done Study (ROADS), i...

The ASCO Post

July 24, 2026

Neoadjuvant Inetetamab Plus Pyrotinib Evaluated in HER2-Positive Locally Advanced Breast Cancer in China

Neoadjuvant treatment with the HER2-targeted monoclonal antibody inetetamab in combination with the irreversible pan-HER tyrosine kinase inhibitor pyrotinib (inhibits HER1, HER2, HER4) and chemotherap...

The ASCO Post

July 24, 2026

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field

The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments fo...

The ASCO Post

July 24, 2026

Discovery Is an Act of Hope: Remembering Dr. Maura Gillison’s Pursuit of Truth

Maura Gillison did not chase awards. She chased answers, and especially clinically impactful answers. That distinction between the pursuit of recognition and the pursuit of truth defined everything ab...

The ASCO Post

July 24, 2026

ASCO 2026: Multiple Myeloma Studies Highlight Advances Across the Field

The plasma cell dyscrasia oral abstract session at the 2026 ASCO Annual Meeting featured several pivotal trials that advanced the field, including those highlighted here. Coverage of new treatments fo...

The ASCO Post